Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-Blind Phase 3 Extension Trial of Glepaglutide in Short Bowel Syndrome
2018-001429-26Phase 3Unknown
- Sponsor
- Zealand Pharma
- Start
- Feb 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, double-blind trial of glepaglutide in short bowel syndrome (SBS), sponsored by Zealand Pharma. Primary endpoint: Safety endpoints. Status: unknown.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2018-001429-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001429-26.